FDA approves bilateral ultrasound for Parkinson’s symptoms
The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the…
Articles by Andrea Lobo
Target enrollment complete in Phase 1b trial of GT-02287
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s…
Immune T cell response may detect Parkinson’s before symptom onset
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the…
Link between RAB32 mutation, Parkinson’s focus of research grant
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently…
NLRP3 inhibitor found safe, well tolerated in Parkinson’s trial
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to…
Phase 3 trial of prasinezumab in early-stage Parkinson’s planned
Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage…
Rune Labs, Parkinson’s Foundation to study digital biomarkers
Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics…
SLEIPNIR clinical trial platform to test 3 Parkinson’s drugs at once
Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments…
Study reinforces inflammation’s role in Parkinson’s development
Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to…
Apathy treatment IRL757 found safe in multiple doses
Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a…